These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35490415)

  • 61. Nonalcoholic Steatohepatitis: A Review.
    Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
    JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China.
    Yang RX; Zou ZS; Zhong BH; Deng H; He FP; Shi JP; Zhao CY; Mi YQ; Zhou YJ; Di FS; Zheng RD; Du Q; Shang J; Popovic B; Chen J; Fan JG
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):426-432. PubMed ID: 34246549
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A population-based study on the prevalence of NASH using scores validated against liver histology.
    Hyysalo J; Männistö VT; Zhou Y; Arola J; Kärjä V; Leivonen M; Juuti A; Jaser N; Lallukka S; Käkelä P; Venesmaa S; Simonen M; Saltevo J; Moilanen L; Korpi-Hyövalti E; Keinänen-Kiukaanniemi S; Oksa H; Orho-Melander M; Valenti L; Fargion S; Pihlajamäki J; Peltonen M; Yki-Järvinen H
    J Hepatol; 2014 Apr; 60(4):839-46. PubMed ID: 24333862
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis.
    Gurka MJ; Mack JA; Chi X; DeBoer MD
    J Gastroenterol Hepatol; 2021 Jan; 36(1):249-256. PubMed ID: 32506513
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
    Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
    Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.
    Ampuero J; Aller R; Gallego-Durán R; Banales JM; Crespo J; García-Monzón C; Pareja MJ; Vilar-Gómez E; Caballería J; Escudero-García D; Gomez-Camarero J; Calleja JL; Latorre M; Albillos A; Salmeron J; Aspichueta P; Lo Iacono O; Francés R; Benlloch S; Fernández-Rodríguez C; García-Samaniego J; Estévez P; Andrade RJ; Turnes J; Romero-Gómez M;
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1260-1270. PubMed ID: 30353552
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Calleja JL; García-Monzón C; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Albillos A; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Guerra MH; Augustín S; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero Gómez M;
    J Hepatol; 2020 Jul; 73(1):17-25. PubMed ID: 32147361
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Descriptive study of hepatic steatosis and associated morbidity in Primary Care. (ESTEATOAP Study)].
    Cortés Rubio JA; Costa Zamora P; Guerra Díaz R; Candela Fernández M; Cortés Costa M
    Semergen; 2020 Sep; 46(6):400-405. PubMed ID: 32249131
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Endoplasmic Reticulum and Mitochondria Contacts Correlate with the Presence and Severity of NASH in Humans.
    Jin C; Felli E; Lange NF; Berzigotti A; Gracia-Sancho J; Dufour JF
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955482
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic.
    Roberts KK; Cochet AE; Lamb PB; Brown PJ; Battafarano DF; Brunt EM; Harrison SA
    Aliment Pharmacol Ther; 2015 Feb; 41(3):293-300. PubMed ID: 25521607
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.
    Lazarus JV; Ekstedt M; Marchesini G; Mullen J; Novak K; Pericàs JM; Roel E; Romero-Gómez M; Ratziu V; Tacke F; Cortez-Pinto H; Anstee QM;
    J Hepatol; 2020 Jan; 72(1):14-24. PubMed ID: 31518646
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Non-alcoholic fatty liver disease: A growing public health problem in Turkey.
    Kaya E; Yılmaz Y
    Turk J Gastroenterol; 2019 Oct; 30(10):865-871. PubMed ID: 31258135
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
    Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
    Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Metabolically healthy and unhealthy obesity phenotypes in the general population: the FIN-D2D Survey.
    Pajunen P; Kotronen A; Korpi-Hyövälti E; Keinänen-Kiukaanniemi S; Oksa H; Niskanen L; Saaristo T; Saltevo JT; Sundvall J; Vanhala M; Uusitupa M; Peltonen M
    BMC Public Health; 2011 Oct; 11():754. PubMed ID: 21962038
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lipid profile pattern in pediatric overweight population with or without NAFLD in relation to IDF criteria for metabolic syndrome: a preliminary study.
    Bălănescu A; Bălănescu P; Comănici V; Stan I; Acs B; Prisăcariu L; Brezan F; Ciomârtan T; Gherghina I
    Rom J Intern Med; 2018 Mar; 56(1):47-54. PubMed ID: 29080393
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity.
    Peng L; Wu S; Zhou N; Zhu S; Liu Q; Li X
    BMC Pediatr; 2021 Mar; 21(1):122. PubMed ID: 33711964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.